C4 Therapeutics, Inc. CCCC
We take great care to ensure that the data presented and summarized in this overview for C4 Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CCCC
View all-
State Street Corp Boston, MA7.15MShares$39.2 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.33MShares$23.7 Million0.19% of portfolio
-
Lynx1 Capital Management LP San Juan, PR3.63MShares$19.9 Million7.73% of portfolio
-
Commodore Capital LP New York, NY3.41MShares$18.7 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.92MShares$16 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.46MShares$13.5 Million1.64% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.44MShares$13.3 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.12MShares$11.6 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC1.86MShares$10.2 Million0.0% of portfolio
-
Silverarc Capital Management, LLC1.44MShares$7.87 Million3.94% of portfolio
Latest Institutional Activity in CCCC
Top Purchases
Top Sells
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Insider Transactions at CCCC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 01
2024
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,389
+1.22%
|
$11,112
$8.1 P/Share
|
Apr 01
2024
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,697
+6.7%
|
$13,576
$8.1 P/Share
|
Apr 01
2024
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,358
+5.8%
|
$10,864
$8.1 P/Share
|
Feb 15
2024
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,560
-3.02%
|
$45,920
$7.9 P/Share
|
Feb 14
2024
|
Mark Mossler Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,290
+48.03%
|
-
|
Feb 14
2024
|
Kelly Schick Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,300
+34.32%
|
-
|
Feb 14
2024
|
Jolie Siegel Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,300
+34.32%
|
-
|
Feb 14
2024
|
Leonard Reyno Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,700
+27.25%
|
-
|
Feb 14
2024
|
Andrew Hirsch President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
103,400
+32.24%
|
-
|
Feb 14
2024
|
Kendra Adams Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,700
+30.91%
|
-
|
Feb 14
2024
|
Scott N Boyle Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,300
+34.28%
|
-
|
Feb 14
2024
|
Stewart Fisher Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,300
+17.45%
|
-
|
Feb 13
2024
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-6.5%
|
$10,410
$6.53 P/Share
|
Feb 13
2024
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-6.5%
|
$10,410
$6.53 P/Share
|
Feb 13
2024
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-2.79%
|
$7,806
$6.53 P/Share
|
Feb 13
2024
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-6.48%
|
$10,410
$6.53 P/Share
|
Feb 13
2024
|
Stewart Fisher Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,255
-2.17%
|
$13,530
$6.53 P/Share
|
Jan 02
2024
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,108
+8.77%
|
$12,648
$6.52 P/Share
|
Jan 02
2024
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,725
+1.53%
|
$10,350
$6.52 P/Share
|
Jan 02
2024
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,687
+7.53%
|
$10,122
$6.52 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 434K shares |
---|---|
Exercise of conversion of derivative security | 18.8K shares |
Payment of exercise price or tax liability | 20.8K shares |
---|